In this Oct. 30, 2007, file photo, employees are silhouetted at the Boehringer Ingelheim pharmaceutical factory in Ingelheim, central Germany. Boehringer Ingelheim has asked the Food and Drug Administration to approve its drug flibanserin for women who report a lack of sexual desire, a market that drugmakers have been targeting for more than a decade since the success of Viagra in men. Federal health regulators said Wednesday, June 16, 2010, the first pill designed to boost the female sex drive failed to make a significant impact on libido in two studies.(AP Photo/Michael Pobst, file)

Photo by: MICHAEL PROBST

In this Oct. 30, 2007, file photo, employees are silhouetted at the Boehringer Ingelheim pharmaceutical factory in Ingelheim, central Germany. Boehringer Ingelheim has asked the Food and Drug Administration to approve its drug flibanserin for women who report a lack of sexual desire, a market that drugmakers have been targeting for more than a decade since the success of Viagra in men. Federal health regulators said Wednesday, June 16, 2010, the first pill designed to boost the female sex drive failed to make a significant impact on libido in two studies.(AP Photo/Michael Pobst, file)